NASDAQ$IMUX
Immunic Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
Immunic reported its Q3 2022 financial results, highlighting a cash and cash equivalents balance of $72.8 million as of September 30, 2022, and a subsequent $56.4 million net cash raise in October 2022, expected to fund the company into the fourth quarter of 2024. The company is progressing the development of vidofludimus calcium (IMU-838) in multiple sclerosis (MS) and anticipates data from the first of its phase 3 ENSURE trials in relapsing MS by the end of 2025.
- Cash and cash equivalents totaled $72.8 million as of September 30, 2022.
- Net cash of $56.4 million was raised in October 2022, expected to fund Immunic into the fourth quarter of 2024.
- Phase 2 CALLIPER trial in progressive MS continues to enroll patients, with an interim analysis expected in the second half of 2023 and top-line data at the end of 2024.
- Data from the first of phase 3 ENSURE trials in relapsing MS is anticipated by the end of 2025.
Headline financials
Revenue & EPS history
Immunic · Revenue · Quarterly
$0
Forward guidance
Immunic anticipates several clinical milestones, including data from the CALLIPER trial in progressive MS and the ENSURE trials in relapsing MS.
Tailwinds
- CALLIPER trial designed to corroborate the neuroprotective potential of vidofludimus calcium.
- Positive unblinded safety, tolerability and pharmacokinetic (PK) results from Part A (single ascending doses, SAD) and Part B (multiple ascending doses, MAD) of the IMU-856 trial in healthy human subjects.
- Receipt of notice of allowance from the U.S. Patent and Trademark Office for a key composition-of-matter patent for IMU-856, providing protection into at least 2038.
- The design of the ENSURE program provides a straightforward path towards potential regulatory approval in relapsing MS.
- Company is on sound financial footing, having significantly bolstered balance sheet in October with the closing of a $60 million private placement, providing runway through multiple value inflection points into the fourth quarter of 2024.
Headwinds
- Group-level data from the phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis did not show a benefit of the first two active doses tested compared to placebo.
- Full and final analysis of data from the IMU-935 trial is needed to understand early observations and determine the best next steps for this key program.
- R&D expenses increased by $7.8 million for the nine months ended September 30, 2022.
- G&A expenses increased by $1.6 million for the nine months ended September 30, 2022.
- Loss on an intercompany loan between Immunic, Inc. and Immunic AG increased by $1.2 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+0.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
-4.5%
Avg return
30 days after
37%
17 / 46 earnings
Positive
+37.0%
Q2 2022
Best reaction
-16.4%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.8% | -1.7% | +15.5% | |
| Q3 2025 | -6.3% | +0.0% | -18.2% | |
| Q4 2024 | -2.1% | -28.1% | -22.7% | |
| Q1 2025 | -4.8% | -7.8% | -26.4% | |
| Q3 2024 | +0.0% | -2.5% | +8.5% | |
| Q1 2024 | -10.1% | -9.1% | -10.9% | |
| Q4 2023 | -4.7% | +8.6% | +3.1% | |
| Q3 2023 | +3.2% | +9.4% | +50.7% | |
| Q2 2023 | -6.9% | -8.8% | -20.4% | |
| Q1 2023 | -2.8% | -5.0% | -3.9% | |
| Q4 2022 | +0.0% | +4.8% | -21.7% | |
| Q3 2022 | -11.1% | -12.3% | -20.5% | |
| Q2 2022 | +37.0% | +29.0% | +16.7% | |
| Q1 2022 | +0.4% | +12.1% | -25.1% | |
| Q4 2021 | -9.4% | -3.2% | -0.4% | |
| Q3 2021 | +2.1% | +1.1% | -16.7% | |
| Q2 2021 | +21.7% | +17.1% | +25.5% | |
| Q1 2021 | -8.3% | -8.1% | -2.8% | |
| Q4 2020 | +0.5% | -1.7% | -5.7% | |
| Q3 2020 | +4.4% | +7.3% | +10.7% | |
| Q2 2020 | +27.9% | +8.7% | -11.6% | |
| Q1 2020 | +18.3% | +20.3% | +53.9% | |
| Q4 2019 | -16.4% | -19.3% | +19.3% | |
| Q3 2019 | -6.4% | -6.2% | -17.3% | |
| Q2 2019 | +0.4% | +4.6% | +6.4% | |
| Q1 2019 | +7.1% | -16.1% | -58.8% | |
| Q4 2018 | -11.1% | -8.3% | -17.8% | |
| Q3 2018 | -7.0% | -9.9% | -18.9% | |
| Q2 2018 | -2.8% | +6.8% | -17.0% | |
| Q1 2018 | +0.9% | +2.7% | -11.7% | |
| Q4 2017 | -6.5% | +2.6% | +0.0% | |
| Q3 2017 | -4.5% | +4.5% | -7.3% | |
| Q2 2017 | +17.3% | +11.5% | +17.3% | |
| Q1 2017 | -4.0% | -17.3% | -17.3% | |
| Q4 2016 | -1.2% | +1.2% | -11.6% | |
| Q3 2016 | -1.0% | +8.6% | -4.8% | |
| Q2 2016 | +1.3% | -0.5% | -5.8% | |
| Q1 2016 | +3.9% | — | — | |
| Q4 2015 | -4.9% | — | — | |
| Q3 2015 | -3.9% | — | — | |
| Q2 2015 | +15.8% | — | — | |
| Q1 2015 | -5.6% | — | — | |
| Q4 2014 | -9.0% | — | — | |
| Q3 2014 | +5.0% | — | — | |
| Q2 2014 | -7.2% | — | — | |
| Q1 2014 | -0.1% | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro